Abstract:Background: Carcinoma of unknown primary (CUP) is a subset of metastatic cancers in which the primary tissue source of the cancer cells remains unidentified. CUP is the eighth most common malignancy worldwide, accounting for up to 5% of all malignancies. Representing an exceptionally aggressive metastatic cancer, the median survival is approximately 3 to 6 months. The tissue in which cancer arises plays a key role in our understanding of sensitivities to various forms of cell death. Thus, the lack of knowledge on the tissue of origin (TOO) makes it difficult to devise tailored and effective treatments for patients with CUP. Developing quick and clinically implementable methods to identify the TOO of the primary site is crucial in treating patients with CUP. Noncoding RNAs may hold potential for origin identification and provide a robust route to clinical implementation due to their resistance against chemical degradation. Objective: This study aims to investigate the potential of microRNAs, a subset of noncoding RNAs, as highly accurate biomarkers for detecting the TOO through data-driven, machine learning approaches for metastatic cancers. Methods: We used microRNA expression data from The Cancer Genome Atlas data set and assessed various machine learning approaches, from simple classifiers to deep learning approaches. As a test of our classifiers, we evaluated the accuracy on a separate set of 194 primary tumor samples from the Sequence Read Archive. We used permutation feature importance to determine the potential microRNA biomarkers and assessed them with principal component analysis and t-distributed stochastic neighbor embedding visualizations. Results: Our results show that it is possible to design robust classifiers to detect the TOO for metastatic samples on The Cancer Genome Atlas data set, with an accuracy of up to 97% (351/362), which may be used in situations of CUP. Our findings show that deep learning techniques enhance prediction accuracy. We progressed from an initial accuracy prediction of 62.5% (226/362) with decision trees to 93.2% (337/362) with logistic regression, finally achieving 97% (351/362) accuracy using deep learning on metastatic samples. On the Sequence Read Archive validation set, a lower accuracy of 41.2% (77/188) was achieved by the decision tree, while deep learning achieved a higher accuracy of 80.4% (151/188). Notably, our feature importance analysis showed the top 3 most important features for predicting TOO to be microRNA-10b, microRNA-205, and microRNA-196b, which aligns with previous work. Conclusions: Our findings highlight the potential of using machine learning techniques to devise accurate tests for detecting TOO for CUP. Since microRNAs are carried throughout the body via extracellular vesicles secreted from cells, they may serve as key biomarkers for liquid biopsy due to their presence in blood plasma. Our work serves as a foundation toward developing blood-based cancer detection tests based on the presence of microRNA.

TOD-CUP: a Gene Expression Rank-Based Majority Vote Algorithm for Tissue Origin Diagnosis of Cancers of Unknown Primary

A Naive Bayes Algorithm for Tissue Origin Diagnosis (Tod-Bayes) of Synchronous Multifocal Tumors in the Hepatobiliary and Pancreatic System

A cross-cohort computational framework to trace tumor tissue-of-origin based on RNA sequencing

Evaluating DNA Methylation, Gene Expression, Somatic Mutation, and Their Combinations in Inferring Tumor Tissue-of-Origin

CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence

A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary

Development and Clinical Validation of a 90-Gene Expression Assay for Identifying Tumor Tissue Origin

TOOme: A Novel Computational Framework to Infer Cancer Tissue-of-Origin by Integrating Both Gene Mutation and Expression

Identiifcation and validation of a novel gene expression signature for diagnosing tumor tissue origin

Predicting Cancer Tissue-of-Origin by a Machine Learning Method Using DNA Somatic Mutation Data.

Deep Learning-based Computational Pathology Predicts Origins for Cancers of Unknown Primary

Prediction of tumor origin in cancers of unknown primary origin with cytology-based deep learning

New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges

A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation.

Deep Learning-Based Identification of Tissue of Origin for Carcinomas of Unknown Primary Using MicroRNA Expression: Algorithm Development and Validation

Diagnostic efficacy of deep learning-based prediction of origin for patients with cancers of unknown primary.

Pan-cancer Transcriptome Analysis Reveals a Gene Expression Signature for the Identification of Tumor Tissue Origin.

Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel

Utility of liquid biopsy for predicting cancer type and informing treatment of carcinoma with unknown primary.

Validation of a 90-Gene Assay for Tissue Origin Diagnosis of Brain Metastases.

Comprehensive genomic and clinical analysis of cancer of unknown primary site in Chinese patients.